Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;125(7 Suppl):S2-5.
doi: 10.1016/j.amjmed.2012.04.014.

Epidemiology of myelodysplastic syndromes

Xiaomei Ma  1
Affiliations
Review

Epidemiology of myelodysplastic syndromes

Xiaomei Ma. Am J Med. 2012 Jul.

Abstract

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem cell malignancies with significant morbidity and high mortality. The incidence of MDS increases markedly with age, and the disease is most prevalent in individuals who are white and male. It is conservatively estimated that >10,000 new cases of MDS occur in the United States annually, and that ≥ 60,000 individuals with MDS currently reside in the country. With an aging population and an improving awareness of the disease, the documented disease burden is expected to escalate in the near future. Recent studies have identified new or inconsistent etiologic factors that warrant further research. Given the poor survival of individuals with MDS, it is important to identify prognostic factors to better risk-stratify patients for more effective treatment. The relevance of different comorbidities to MDS prognosis and the potential interaction between various comorbidities represents an interesting area of research.

PubMed Disclaimer

Figures

Figure
Figure
Incidence rate of myelodysplastic syndromes (MDS) in different age groups in the United States (2001 to 2008). (Adapted from NCI SEER*Stat Database.)
See this image and copyright information in PMC

References

    1. Fritz A, Percy C, Jack A, Shanmugarathan S, Sobin L, Parkin DM, Whelan S, editors. International Classification of Diseases for Oncology (ICD-O) 3. Geneva: World Health Organization; 2000.
    1. Schumacher HR, Nand S. Myelodysplastic Syndromes: Approach to Diagnosis and Treatment. New York: Igaku-Shoin Medical Publishers; 1995.
    1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542. - PubMed
    1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52. - PubMed
    1. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847–2852. - PubMed

Publication types